Biologics before triple therapy not cost effective for rheumatoid arthritis

(American College of Physicians) Stepping up to biologic therapy when methotrexate monotherapy fails offers minimal incremental benefit over using a combination of drugs known as triple therapy, yet incurs large costs for treating rheumatoid arthritis (RA). Results of a comprehensive cost-effectiveness analysis suggest that patients who have RA and no contraindications to triple therapy should use it prior to a biologic as the next regimen. The study is published in Annals of Internal Medicine.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news